The ability of nuclear magnetic resonance (NMR) spectroscopy to distinguish normal, diseased non-neoplastic, and neoplastic human breast tissues was investigated with T1 and T2 relaxation times used. The results indicated that NMR relaxation times could distinguish between the mean values of breast neoplasms and other diseased or normal tissues, with P values less than 0.001. Given a single sample, the probability of classifying it nonneoplastic or carcinoma could be accomplished with 85% confidence. For human breast tissues, the relaxation time T2 may be more discriminating that T1. These results support the view that the use of NMR spectroscopy in cancer detection may be of significant value and warrants considerable more interest and effort to determine the beneficial applications and limits of this technology.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Analysis of circulating cell-free nuclear and mitochondrial DNA in plasma of Mexican patients with breast cancer.
Gac Med Mex
January 2025
División de Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara.
Background: The usefulness of circulating free DNA (cfDNA), nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) as potential biomarkers in cancer remains controversial.
Objective: To determine the concentration of cfDNA and plasma nDNA and mtDNA levels in breast cancer (BC) patients.
Material And Methods: This study included a total of 86 women (69 patients with BC and 17 women as a control group).
MTHFD2 promotes breast cancer cell proliferation through IFRD1 RNA m6A methylation-mediated HDAC3/p53/mTOR pathway.
Neoplasma
December 2024
Department of Pathology and Forensic Medicine, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
MTHFD2 is highly overexpressed in breast cancer tissues, indicating that it might be used as a target in breast cancer treatment. This study aims to determine the role of MTHFD2 in breast cancer cell proliferation and the molecular pathways involved. In order to investigate MTHFD2 gene expression and its downstream pathways in breast cancer, we started our inquiry with a bioinformatics analysis.
View Article and Find Full Text PDFIFIH1 promotes apoptosis through the TBK1/IRF3 pathway in triple-negative breast cancer.
Neoplasma
December 2024
Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast malignancy. Although some patients benefit from immune checkpoint therapy, current treatment methods rely mainly on chemotherapy. It is imperative to develop predictors of efficacy and identify individuals who will be sensitive to particular treatment regimens.
View Article and Find Full Text PDFClinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.
Breast Cancer Res Treat
January 2025
Center for Discovery and Innovation (CDI), Hackensack Meridian Health, Nutley, NJ, USA.
Purpose: To study the association between clinicopathologic characteristics of ductal carcinoma in situ (DCIS) and risk of subsequent invasive breast cancer (IBC).
Methods: We conducted a case-control study nested in a multicenter, population-based cohort of 8175 women aged ≥ 18 years with DCIS diagnosed between 1987 and 2016 and followed for a median duration of 83 months. Cases (n = 497) were women with a first diagnosis of DCIS who developed a subsequent IBC ≥ 6 months later; controls (2/case; n = 959) were matched to cases on age at and calendar year of DCIS diagnosis.
L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study.
Breast Cancer Res Treat
January 2025
Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Waima Road 114, Jinping District, Shantou, 515041, China.
Purpose: Precise tumor excision is important in breast-conserving surgery (BCS). This study explores the safety and accuracy of fluorescence image-guided BCS (FIGS) using a lidocaine mucilage-ICG compound (L-ICG).
Methods: 54 patients who underwent BCS from August 2020 to September 2023 were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!